After B.Riley FBR and Cantor Fitzgerald assigned a Buy rating to Viewray in the last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Viewray (NASDAQ: VRAY) today and set a price target of $12. The company’s shares closed yesterday at $7.74.
Yang said:
“We also note that ViewRay recently surpassed its 50th order, a major milestone for the company highlighting the strong growing adoption of the MRI Linac.”
According to TipRanks.com, Yang is a 5-star analyst with an average return of 19.6% and a 48.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Alder Biopharmaceuticals, and Audentes Therapeutics.
Currently, the analyst consensus on Viewray is Strong Buy and the average price target is $12.88, representing a 66.4% upside.
In a report issued on May 8, B.Riley FBR also reiterated a Buy rating on the stock with a $13.50 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $10.64 and a one-year low of $4.40. Currently, Viewray has an average volume of 549.4K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the research, development, and manufacture of magnetic resonance imaging (MRI) system. Its product includes MRIdian, which supports image-guided radiation therapy, stereotactic radiation therapy, and radiosurgery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
